Fig. 1: Treatment responses in patients with HR positive, HER2-negative advanced breast cancer stratified by biomarker status. | Nature Communications

Fig. 1: Treatment responses in patients with HR positive, HER2-negative advanced breast cancer stratified by biomarker status.

From: Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial

Fig. 1: Treatment responses in patients with HR positive, HER2-negative advanced breast cancer stratified by biomarker status.

a Waterfall plots of the best percentage changes for the sum of target lesion diameters are shown for individual patients assessed by investigators per RECIST version 1.1. Each bar represents one patient. b Swimmer plots of time to tumor response (months) of individual patients as assessed by investigators. Each lane represents one patient. Source data are provided as a source data file.

Back to article page